<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PROGLYCEM- diazoxide suspension </strong><br>Teva Branded Pharmaceutical Products R&amp;D, Inc.<br></p></div>
<h1><span class="Bold">PROGLYCEM<span class="Sup">®</span><br>brand of diazoxide <br>Capsules <br>Suspension, USP</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9e57f7ff-8fbd-4f72-b77e-17208609f18a"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">FOR ORAL ADMINISTRATION</span></p>
<p><span class="Bold">Rx Only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_5638ee30-3130-41af-b3fd-61e491461c1d"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">PROGLYCEM<span class="Sup">®</span> (diazoxide) is a nondiuretic benzothiadiazine derivative taken orally for the management of symptomatic <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. PROGLYCEM<span class="Sup">®</span><span class="Bold"></span>Capsules contain 50 mg diazoxide, USP. The Suspension contains 50 mg of diazoxide, USP in each milliliter and has a chocolate-mint flavor; alcohol content is approximately 7.25%. Other ingredients: Sorbitol solution, chocolate cream flavor, propylene glycol, magnesium aluminum silicate, carboxymethycellulose sodium, mint flavor, sodium benzoate, methylparaben, poloxamer 188, propylparaben, and purified water. Hydrochloric acid or sodium hydroxide may be added to adjust pH.</p>
<p>Diazoxide has the following structural formula:</p>
<div class="Figure">
<a name="id264"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b16c7832-2fd9-49af-b923-1dc0d91fd6e2&amp;name=image-01.jpg">
</div>
<p>Diazoxide is 7-chloro-3-methyl-2<span class="Italics">H</span>-1,2,4-benzothiadiazine 1,1-dioxide with the empirical formula C<span class="Sub">8</span>H<span class="Sub">7</span>ClN<span class="Sub">2</span>O<span class="Sub">2</span>S and the molecular weight 230.7. It is a white powder practically insoluble to sparingly soluble in water.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_c77cc8e2-8e74-4b49-bb7f-d57d3032f378"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Diazoxide administered orally produces a prompt dose-related increase in blood glucose level, due primarily to an inhibition of insulin release from the pancreas, and also to an extrapancreatic effect.</p>
<p>The hyperglycemic effect begins within an hour and generally lasts no more than eight hours in the presence of normal renal function.</p>
<p>PROGLYCEM<span class="Sup">®</span> decreases the excretion of sodium and water, resulting in <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> which may be clinically significant.</p>
<p>The hypotensive effect of diazoxide on blood pressure is usually not marked with the oral preparation. This contrasts with the intravenous preparation of diazoxide (see <a href="#i4i_adverse_effects_ID_ar">ADVERSE REACTIONS</a>).</p>
<p>Other pharmacologic actions of PROGLYCEM<span class="Sup">®</span> include increased pulse rate; increased serum uric acid levels due to decreased excretion; increased serum levels of free fatty acids' decreased chloride excretion; decreased para-aminohippuric acid; (PAH) clearance with no appreciable effect on glomerular filtration rate.</p>
<p>The concomitant administration of a benzothiazide diuretic may intensify the hyperglycemic and hyperuricemic effects of PROGLYCEM<span class="Sup">®</span>. In the presence of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, hyperglycemic effects are also potentiated.</p>
<p>PROGLYCEM<span class="Sup">®</span>-induced <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> is reversed by the administration of insulin or tolbutamide. The inhibition of insulin release by PROGLYCEM<span class="Sup">®</span> is antagonized by alpha-adrenergic blocking agents.</p>
<p>PROGLYCEM<span class="Sup">®</span> is extensively bound (more than 90%) to serum proteins, and is excreted in the kidneys. The plasma half-life following I.V. administration is 28 ± 8.3 hours. Limited data on oral administration revealed a half-life of 24 and 36 hours in two adults. In four children aged four months to six years, the plasma half-life varied from 9.5 to 24 hours on long-term oral administration. The half-life may be prolonged following overdosage, and in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_ID_iu"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">PROGLYCEM<span class="Sup">®</span> (ORAL DIAZOXIDE) is useful in the management of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> due to <span class="product-label-link" type="condition" conceptid="4307509" conceptname="Hyperinsulinism">hyperinsulinism</span> associated with the following conditions:</p>
<dl>
<dt> </dt>
<dd>Adults: Inoperable islet cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenoma</span> or carcinoma, or extrapancreatic malignancy.</dd>
<dt> </dt>
<dd>Infants and Children: Leucine sensitivity, islet cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, nesidioblastosis, extrapancreatic malignancy, islet cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenoma</span>, or adenomatosis. PROGLYCEM<span class="Sup">®</span> may be used preoperatively as a temporary measure, and postoperatively, if <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> persists.</dd>
</dl>
<p>PROGLYCEM<span class="Sup">®</span> should be used only after a diagnosis of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> due to one of the above conditions has been definitely established. When other specific medical therapy or surgical management either has been unsuccessful or is not feasible, treatment with PROGLYCEM<span class="Sup">®</span> should be considered.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_cf78eb99-0f48-4135-98be-c7cc60f3dc80"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">The use of PROGLYCEM<span class="Sup">®</span> for functional <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> is contraindicated. The drug should not be used in patients hypersensitive to diazoxide or to other thiazides unless the potential benefits outweigh the possible risks.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_da916f3b-183f-4c64-aa4e-f6fc5d396422"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">The antidiuretic property of diazoxide may lead to significant <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, which in patients with compromised cardiac reserve, may precipitate <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. The <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> will respond to conventional therapy with diuretics.</p>
<p>It should be noted that concomitantly administered thiazides may potentiate the hyperglycemic and hyperuricemic actions of diazoxide (See <a href="#i4i_interactions_ID_predi">DRUG INTERACTIONS</a> and <a href="#i4i_animal_pharmacology_ID_ap">ANIMAL PHARMACOLOGY AND/OR TOXICOLOGY</a>).</p>
<p><span class="product-label-link" type="condition" conceptid="4209145" conceptname="Ketoacidosis">Ketoacidosis</span> and nonketotic hyperosmolar <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> have been reported in patients treated with recommended doses of PROGLYCEM<span class="Sup">®</span> usually during intercurrent illness. Prompt recognition and treatment are essential (See <a href="#i4i_overdosage_ID_od">OVERDOSAGE</a>), and prolonged surveillance following the acute episode is necessary because of the long drug half-life of approximately 30 hours. The occurrence of these serious events may be reduced by careful education of patients regarding the need for monitoring the urine for sugar and <span class="product-label-link" type="condition" conceptid="4017413" conceptname="Acetoacetate">ketones</span> and for prompt reporting of abnormal findings and unusual symptoms to the physician. Transient <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span> occurred in association with hyperosmolar <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> in an infant, and subsided on correction of the hyper-osmolarity. <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">Cataracts</span> have been observed in several animals receiving daily doses of intravenous or oral diazoxide.</p>
<p>The development of abnormal facial features in four children treated chronically (&gt;4 years) with PROGLYCEM<span class="Sup">®</span> for <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> <span class="product-label-link" type="condition" conceptid="4307509" conceptname="Hyperinsulinism">hyperinsulinism</span> in the same clinic has been reported.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">Pulmonary Hypertension</span> in Neonates and Infants</span></p>
<p>There have been postmarketing reports of <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> occurring in infants and neonates treated with diazoxide. The cases were reversible upon discontinuation of the drug. Monitor patients, especially those with risk factors for <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>, for <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> and discontinue diazoxide if <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> is suspected.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_47bf0fcd-8883-459a-9791-0c913c62e24d"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_b198b974-e4b8-4e44-afe3-8d52e0ad924a"></a><a name="section-7.1"></a><p></p>
<h2>General:</h2>
<p class="First">Treatment with PROGLYCEM<span class="Sup">®</span> should be initiated under close clinical supervision, with careful monitoring of blood glucose and clinical response until the patient's condition has stabilized. This usually requires several days. If not effective in two to three weeks, the drug should be discontinued.</p>
<p>Prolonged treatment requires regular monitoring of the urine for sugar and <span class="product-label-link" type="condition" conceptid="4017413" conceptname="Acetoacetate">ketones</span>, especially under stress conditions, with prompt reporting of any abnormalities to the physician. Additionally, blood sugar levels should be monitored periodically by the physician to determine the need for dose adjustment.</p>
<p>The effects of diazoxide on the hematopoietic system and the level of serum uric acid should be kept in mind; the latter should be considered particularly in patients with <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> or a history of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>.</p>
<p>In some patients, higher blood levels have been observed with the oral suspension than with the capsule formulation of PROGLYCEM<span class="Sup">®</span>. Dosage should be adjusted as necessary in individual patients if changed from one formulation to the other.</p>
<p>Since the plasma half-life of diazoxide is prolonged in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, a reduced dosage should be considered. Serum electrolyte levels should also be evaluated for such patients.</p>
<p>The antihypertensive effect of other drugs may be enhanced by PROGLYCEM<span class="Sup">®</span>, and this should be kept in mind when administering it concomitantly with antihypertensive agents.</p>
<p>Because of the protein binding, administration of PROGLYCEM<span class="Sup">®</span> with coumarin or its derivatives may require reduction in the dosage of the anticoagulant, although there has been no reported evidence of excessive anticoagulant effect. In addition, PROGLYCEM<span class="Sup">®</span> may possibly displace bilirubin from albumin; this should be kept in mind particularly when treating newborns with increased <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">bilirubinemia</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">Pulmonary hypertension</span> has been reported in neonates and young infants treated with diazoxide. (see <a href="#i4i_warnings_id_da916f3b-183f-4c64-aa4e-f6fc5d396422">WARNINGS</a>)</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_9fd80014-ff20-48df-a3a2-7066070e656f"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients:</h2>
<p class="First">During treatment with PROGLYCEM<span class="Sup">®</span> the patient should be advised to consult regularly with the physician and to cooperate in the periodic monitoring of his condition by laboratory tests. In addition, the patient should be advised:</p>
<dl>
<dt>•</dt>
<dd>to take the drug on a regular schedule as prescribed, not to skip doses, not to take extra doses;</dd>
<dt>•</dt>
<dd>not to use this drug with other medications unless this is done with the physician's advice;</dd>
<dt>•</dt>
<dd>not to allow anyone else to take this medication;</dd>
<dt>•</dt>
<dd>to follow dietary instructions;</dd>
<dt>•</dt>
<dd>to report promptly any adverse effects (i.e., <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">increased urinary frequency</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">increased thirst</span>, fruity <span class="product-label-link" type="condition" conceptid="4195873" conceptname="Breath smells unpleasant">breath odor</span>);</dd>
<dt>•</dt>
<dd>to report pregnancy or to discuss plans for pregnancy.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_af7f8be4-0267-4040-970a-bf535185e9ca"></a><a name="section-7.3"></a><p></p>
<h2>Laboratory tests:</h2>
<p class="First">The following procedures may be especially important in patient monitoring (not necessarily inclusive); blood glucose determinations (recommended at periodic intervals in patients taking diazoxide orally for treatment of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, until stabilized); blood urea nitrogen (BUN) determinations and creatinine clearance determinations; hematocrit determinations; platelet count determinations; total and differential leukocyte counts; serum <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> (AST) level determinations; serum uric acid level determinations; and urine testing for glucose and <span class="product-label-link" type="condition" conceptid="4017413" conceptname="Acetoacetate">ketones</span> (in patients being treated with diazoxide for <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, semiquantitative estimation of sugar and <span class="product-label-link" type="condition" conceptid="4017413" conceptname="Acetoacetate">ketones</span> in serum performed by the patient and reported to the physician provides frequent and relatively inexpensive monitoring of the condition).</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_ID_predi"></a><a name="section-7.4"></a><p></p>
<h2>Drug Interactions:</h2>
<p class="First">Since diazoxide is highly bound to serum proteins, it may displace other substances which are also bound to protein, such as bilirubin or coumarin and its derivatives, resulting in higher blood levels of these substances. Concomitant administration of oral diazoxide and diphenylhydantoin may result in a loss of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> control. These potential interactions must be considered when administering PROGLYCEM<span class="Sup">®</span> Capsules or Suspension.</p>
<p>The concomitant administration of thiazides or other commonly used diuretics may potentiate the hyperglycemic and hyperuricemic effects of diazoxide.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_2cea1e58-3cb2-45a4-8c79-189db3c15fe5"></a><a name="section-7.5"></a><p></p>
<h2>Drug/Laboratory Test Interactions:</h2>
<p class="First">The hyperglycemic and hyperuricemic effects of diazoxide preclude proper assessment of these metabolic states. Increased renin secretion, IgG concentrations and decreased cortisol secretions have also been noted. Diazoxide inhibits glucagon-stimulated insulin release and causes a false-negative insulin response to glucagon.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_b6d7baa7-886d-4544-82ea-dc0af12ab4a2"></a><a name="section-7.6"></a><p></p>
<h2>Carcinogenesis, mutagenesis, impairment of fertility:</h2>
<p class="First">No long-term animal dosing study has been done to evaluate the carcinogenic potential of diazoxide. No laboratory study of mutagenic potential or animal study of effects on fertility has been done.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_ff7124ed-4710-4f6d-be70-14425bb190ae"></a><a name="section-7.7"></a><p></p>
<h2>Pregnancy Category C:</h2>
<p class="First">Reproduction studies using the oral preparation in rats have revealed increased fetal resorptions and delayed parturition, as well as fetal skeletal anomalies; evidence of skeletal and cardiac teratogenic effects in rabbits has been noted with intravenous administration. The drug has also been demonstrated to cross the placental barrier in animals and to cause degeneration of the fetal pancreatic beta cells (See <a href="#i4i_animal_pharmacology_ID_ap">ANIMAL PHARMACOLOGY AND/OR TOXICOLOGY</a>). Since there are no adequate data on fetal effects of this drug when given to pregnant women, safety in pregnancy has not been established. When the use of PROGLYCEM<span class="Sup">®</span> is considered, the indications should be limited to those specified above for adults (See <a href="#i4i_indications_ID_iu">INDICATIONS AND USAGE</a>), and the potential benefits to the mother must be weighed against possible harmful effects to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="i4i_non_teratogenic_id_c8aa8ebb-2791-46ab-abdf-a7cef3b2fc85"></a><a name="section-7.8"></a><p></p>
<h2>Non-teratogenic effects:</h2>
<p class="First">Diazoxide crosses the placental barrier and appears in cord blood. When given to the mother prior to delivery of the infant, the drug may produce fetal or neonatal <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, altered carbohydrate metabolism, and possibly other side effects that have occurred in adults.</p>
<p><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span> and <span class="product-label-link" type="condition" conceptid="443793" conceptname="Hypertrichosis">hypertrichosis</span> lanuginosa have occurred in infants whose mothers received oral diazoxide during the last 19 to 60 days of pregnancy.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_c623f92b-a14f-4395-ad5d-a5820c685fdc"></a><a name="section-7.9"></a><p></p>
<h2>Labor and delivery:</h2>
<p class="First">Since intravenous administration of the drug during labor may cause cessation of uterine contractions, and administration of oxytocic agents may be required to reinstate labor, caution is advised in administering PROGLYCEM<span class="Sup">®</span> at that time.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_cdd9d285-fde2-4615-a652-ebdc0fe9ea3a"></a><a name="section-7.10"></a><p></p>
<h2>Nursing mothers:</h2>
<p class="First">Information is not available concerning the passage of diazoxide in breast milk. Because many drugs are excreted in human milk and because of the potential for adverse reactions from diazoxide in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_04c3b67f-de35-43e8-a655-06ab52ba8762"></a><a name="section-7.11"></a><p></p>
<h2>Pediatric use:</h2>
<p class="First">(See <a href="#i4i_indications_ID_iu">INDICATIONS AND USAGE</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_ID_ar"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS:</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_327a8d57-7fad-4430-8162-adff01b7a8a2"></a><a name="section-8.1"></a><p></p>
<h2><span class="Italics">Frequent and Serious:</span></h2>
<p class="First">Sodium and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> is most common in young infants and in adults and may precipitate <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> in patients with compromised cardiac reserve. It usually responds to diuretic therapy (See <a href="#i4i_interactions_ID_predi">DRUG INTERACTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ba217044-9339-4b81-94db-ab44ec801e88"></a><a name="section-8.2"></a><p></p>
<h2><span class="Italics">Infrequent but Serious:</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">Diabetic ketoacidosis</span> and hyperosmolar nonketotic <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> may develop very rapidly. Conventional therapy with insulin and restoration of fluid and electrolyte balance is usually effective if instituted promptly. Prolonged surveillance is essential in view of the long half-life of PROGLYCEM<span class="Sup">®</span> (See <a href="#i4i_overdosage_ID_od">OVERDOSAGE</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ade1f127-17f0-4a4c-8692-6da87ce931bc"></a><a name="section-8.3"></a><p></p>
<h2><span class="Italics">Other frequent adverse reactions:</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">Hirsutism</span> of the lanugo type, mainly on the forehead, back and limbs, occurs most commonly in children and women and may be cosmetically unacceptable. It subsides on discontinuation of the drug.</p>
<p><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> or <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span> may require reduction in dosage in order to avoid progression to <span class="product-label-link" type="condition" conceptid="4209145" conceptname="Ketoacidosis">ketoacidosis</span> or hyperosmolar <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>.</p>
<p>Gastrointestinal intolerance may include <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, transient <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">loss of taste</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, increased levels of serum uric acid are common.</p>
<p><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> with or without <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span> may require discontinuation of the drug. <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> is transient, is not associated with increased susceptibility to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and ordinarily does not require discontinuation of the drug. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> may also occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4901a518-763d-41a5-b6ff-de46010d799b"></a><a name="section-8.4"></a><p></p>
<h2><span class="Italics">Other adverse reactions which have been observed are:</span></h2>
<p class="First"><span class="Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs occasionally, which may be augmented by thiazide diuretics given concurrently. A few cases of transient <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, for which no explanation is apparent, have been noted. <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span> has been reported rarely.  <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">Pulmonary hypertension</span> has been reported in neonates and young infants (see <a href="#i4i_warnings_id_da916f3b-183f-4c64-aa4e-f6fc5d396422">WARNINGS</a>).</p>
<p><span class="Italics">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>; <span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">decreased hemoglobin</span> / hematocrit; excessive <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, decreased IgG.</p>
<p><span class="Italics">Hepato-renal:</span> increased AST, alkaline phosphatase; <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, decreased creatinine clearance, reversible <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>, decreased urinary output, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span>. Neurologic: <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4174262" conceptname="Polyneuropathy">polyneuritis</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, extrapyramidal signs. </p>
<p><span class="Italics">Ophthalmologic:</span> transient <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span>, <span class="product-label-link" type="condition" conceptid="378756" conceptname="Conjunctival hemorrhage">subconjunctival hemorrhage</span>, ring <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">scotoma</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>. <span class="Italics">Skeletal, integumentary;</span> monilial <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, herpes, advance in bone age; loss of scalp hair. <span class="Italics">Systemic:</span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>. <span class="Italics">Other;</span> <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout acute</span> pancreatitis/<span class="product-label-link" type="condition" conceptid="4080069" conceptname="Necrosis of pancreas">pancreatic necrosis</span>, <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>, enlargement of lump in breast.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_ID_od"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">An overdosage of PROGLYCEM<span class="Sup">®</span> causes marked <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> which may be associated with <span class="product-label-link" type="condition" conceptid="4209145" conceptname="Ketoacidosis">ketoacidosis</span>. It will respond to prompt insulin administration and restoration of fluid and electrolyte balance. Because of the drug's long half-life (approximately 30 hours), the symptoms of overdosage require prolonged surveillance for periods up to seven days until the blood sugar level stabilizes within the normal range. One investigator reported successful lowering of diazoxide blood levels by peritoneal dialysis in one patient and by hemodialysis in another.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_d46116aa-dc5e-4325-9f5b-73522cee6aca"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Patients should be under close clinical observation when treatment with PROGLYCEM<span class="Sup">®</span> is initiated. The clinical response and blood glucose level should be carefully monitored until the patient's condition has stabilized satisfactory; in most instances, this may be accomplished in several days. If administration of PROGLYCEM<span class="Sup">®</span> is not effective after two or three weeks, the drug should be discontinued.</p>
<p>The dosage of PROGLYCEM<span class="Sup">®</span> must be individualized based on the severity of the hypoglycemic condition and the blood glucose level and clinical response of the patient. The dosage should be adjusted until the desired clinical and laboratory effects are produced with the least amount of the drug. Special care should be taken to assure accuracy of dosage in infants and young children.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2a997459-e95b-426d-97ba-96671deb0cd6"></a><a name="section-10.1"></a><p></p>
<h2><span class="Italics">Adults and children:</span></h2>
<p class="First">The usual daily dosage is 3 to 8 mg/kg, divided into two or three equal doses every 8 or 12 hours. In certain instances, patients with refractory <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may require higher dosages. Ordinarily, an appropriate starting dosage is 3 mg/kg/day, divided into three equal doses every 8 hours. Thus an average adult would receive a starting dosage of approximately 200 mg daily.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_af80e08b-f401-496c-b914-4a0613abbbf7"></a><a name="section-10.2"></a><p></p>
<h2><span class="Italics">Infants and newborns:</span></h2>
<p class="First">The usual daily dosage is 8 to 15 mg/kg divided into two or three equal doses every 8 to 12 hours. An appropriate starting dosage is 10 mg/kg/day, divided into three equal doses every 8 hours.</p>
</div>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_ID_ap"></a><a name="section-11"></a><p></p>
<h1>ANIMAL PHARMACOLOGY AND/OR TOXICOLOGY</h1>
<p class="First">Oral diazoxide in the mouse, rat, rabbit, dog, pig, and monkey produces a rapid and transient rise in blood glucose levels. In dogs, increased blood glucose is accompanied by increased free fatty acids, lactate, and <span class="product-label-link" type="condition" conceptid="4029769" conceptname="Pyruvic acid">pyruvate</span> in the serum. In mice, a marked decrease in liver glycogen and an increase in the blood urea nitrogen level occur.</p>
<p>In acute toxicity studies the LD50 for oral diazoxide suspension is &gt;5000 mg/kg in the rat, &gt;522 mg/kg in the neonatal rat, between 1900 and 2572 mg/kg in the mouse, and 219 mg/kg in the guinea pig. Although the oral LD<span class="Sub">50</span> was not determined in the dog, a dosage of up to 500 mg/kg was well tolerated.</p>
<p>In subacute oral toxicity studies, diazoxide at 400 mg/kg in the rat produced <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, increases in liver and kidney weights, and adrenal <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span>. Daily dosages up to 1080 mg/kg for three months produced <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, an increase in liver weight and an increase in mortality. In dogs given oral diazoxide at approximately 40 mg/kg/day for one month, no biologically significant gross or microscopic abnormalities were observed. <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">Cataracts</span>, attributed to markedly disturbed carbohydrate metabolism, have been observed in a few dogs given repeated daily doses of oral or intravenous diazoxide. The lenticular changes resembled those which occur experimentally in animals with increased blood glucose levels. In chronic toxicity studies, rats given a daily dose of 200 mg/kg diazoxide for 52 weeks had a decrease in <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and an increase in heart, liver, adrenal and thyroid weights. Mortality in drug-treated and control groups was not different. Dogs treated with diazoxide at dosages of 50, l00, and 200 mg/kg/day for 82 weeks had higher blood glucose levels than controls. Mild bone marrow stimulation and increased pancreas weights were evident in the drug-treated dogs; several developed <span class="product-label-link" type="condition" conceptid="4288544" conceptname="Inguinal hernia">inguinal hernias</span>, one had a testicular seminoma, and another had a <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> near the penis. Two females had inguinal mammary <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swellings</span>. The etiology of these changes was not established. There was no difference in mortality between drug-treated and control groups. In a second chronic oral toxicity study, dogs given milled diazoxide at 50, l00, and 200 mg/kg/day had <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> and sever <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, causing <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in a few. Hematologic, biochemical, and histologic examination did not indicate any cause of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> other than inanition. After one year of treatment, there is no evidence of herniation or tissue <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in any of the dogs.</p>
<p>When diazoxide was administered at high dosages concomitantly with either chlorothiazide to rats or trichlormethiazide to dogs, increased toxicity was observed. In rats, the combination was nephrotoxic; epithelial <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> was observed in the collecting tubules. In dogs, a diabetic syndrome was produced which resulted in <span class="product-label-link" type="condition" conceptid="4101761" conceptname="Ketosis">ketosis</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Neither of the drugs given alone produced these effects.</p>
<p>Although the data are inconclusive, reproduction and teratology studies in several species of animals indicate that diazoxide, when administered during the critical period of embryo formation, may interfere with normal fetal development, possibly through altered glucose metabolism. Parturition was occasionally prolonged in animals treated at term. Intravenous administration of diazoxide to pregnant sheep, goats, and swine produced in the fetus an appreciable increase in blood glucose level and degeneration of the beta cells of the Islets of Langerhans. The reversibility of these effects was not studied.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_46424e35-a7a9-4847-b396-13d4a1a7acd8"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">PROGLYCEM<span class="Sup">®</span> (diazoxide capsules, USP), 50 mg, half opaque orange and half clear capsules, branded in black with BNP 6000: bottle of 100 (NDC 0575-6000-01).</p>
<p>PROGLYCEM<span class="Sup">®</span> suspension, 50 mg/mL, a chocolate-mint flavored suspension; bottle of 30 ml (NDC 0575-6200-30), with dropper calibrated to deliver 10, 20, 30, 40 and 50 mg diazoxide. <br><span class="Bold">Shake well before each use. Protect from light. Store in carton until contents are used. Store in light resistant container as defined in the USP. Store PROGLYCEM<span class="Sup">®</span> Capsules and Suspension at 25°C (77°F) excursions permitted 15°-30°C (59-86°F). [See USP Controlled Room Temperature].</span></p>
<p><span class="Bold">Rx only</span></p>
<p>Distributed by:</p>
<p>Teva Pharmaceuticals USA, Inc.</p>
<p>North Wales, PA 19454</p>
<p>Rev. 9/2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_7ccea8bb-975e-46b0-a920-6994283112be"></a><a name="section-13"></a><p></p>
<h1>Package/Label Display Panel </h1>
<div class="Figure">
<a name="id-106706163"></a><img alt="Proglycem® (diazoxide, USP) Oral Suspension 50 mg/mL, 30 mL Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b16c7832-2fd9-49af-b923-1dc0d91fd6e2&amp;name=image-02.jpg">
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6eb9b207-f1a5-4147-8ac4-c18bee0f39ec"></a><a name="section-13.1"></a><p></p>
<h2>Proglycem® (diazoxide, USP) Oral Suspension 50 mg/mL, 30 mL Carton Text </h2>
<dl>
<dt> </dt>
<dd><span class="Bold">30 mL	NDC 0575-6200-30</span></dd>
</dl>
<p class="First"><span class="Bold">Proglycem</span></p>
<p><span class="Bold">(diazoxide, USP)</span></p>
<p><span class="Bold">ORAL SUSPENSION</span></p>
<p><span class="Bold">50mg</span></p>
<p><span class="Bold">per mL</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">TEVA</span></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PROGLYCEM 		
					</strong><br><span class="contentTableReg">diazoxide suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0575-6200</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DIAZOXIDE</strong> (DIAZOXIDE) </td>
<td class="formItem">DIAZOXIDE</td>
<td class="formItem">50 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM ALUMINUM SILICATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CARBOXYMETHYLCELLULOSE SODIUM, UNSPECIFIED FORM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM BENZOATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLOXAMER 188</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (White to light brown) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">MINT (Chocolate mint) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0575-6200-30</td>
<td class="formItem">1  in 1 BOX</td>
<td class="formItem">09/30/1990</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">30 mL in 1 BOTTLE, DROPPER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017453</td>
<td class="formItem">09/30/1990</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Teva Branded Pharmaceutical Products R&amp;D, Inc.
							(825896603)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 10/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a2410f90-c096-4421-8f1b-04c136018cea</div>
<div>Set id: b16c7832-2fd9-49af-b923-1dc0d91fd6e2</div>
<div>Version: 5</div>
<div>Effective Time: 20151002</div>
</div>
</div> <div class="DistributorName">Teva Branded Pharmaceutical Products R&amp;D, Inc.</div></p>
</body></html>
